Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
  • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/347—Phenols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/35—Ketones, e.g. benzophenone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin

Definitions

• the present invention relates to a method for obtaining a custom cosmetic treatment.
• the activity of these molecules and elements is related to their ability to play a specific role or action in one or more biological pathways. This role includes the ability to interact with elements of our body and to modify some biological processes to obtain a beneficial response for our skin.
• SNPs Single-Nucleotide Polymorphisms
• SNPs Single-Nucleotide Polymorphisms
• the analysis of the presence of SNPs is used for pharmacogenomic studies, i.e., studies designed to evaluate the different efficacy of an active ingredient in the presence or absence of such genetic variations.
• Other SNPs have been identified to evaluate the susceptibility of a patient to develop a particular pathology.
• US 2016/0068904 describes a method for analyzing genetic variants that affect the aesthetic appearance of individuals, in particular of the skin. Said method provides for the analysis of genetic variants, such as the SNPs of some important genes for maintaining the well-being of the skin. Said method provides for the analysis of said SNPs and the use of specific products to be used in the presence of a specific SNP.
• US 2015/0105279 describes a method for customizing cosmetic or nutri-cosmetic treatments. Said method provides for a preventative genetic analysis adapted to help the choice of the active ingredients for skin care. The selected active ingredients will then be used to prepare a cosmetic, cosmeceutical or nutri-cosmetic formulation.
• US 2015/0086104 describes a method for evaluating the skin quality and for the assigning of a score. Said score is evaluated against a maximum score for human skin quality and then the best product or compound for the cosmetic treatment is evaluated. Among the various evaluated factors there is the presence of SNPs in particular genes.
• WO 2014/176425 describes a method for obtaining a custom cosmetic preparation. Said method provides for the analysis of different SNPs including SNP rsl059261 of MMP-1.
• WO 2016/005793 A 1 describes a method for the preparation of a custom cosmetic composition, said method provides for the study of HAS-1 gene, inter alia, and the evaluation of all the SNPs thereof.
• Eunsun Jung et al., Molecules, (2013) describes the use of madecassoside for the formulation of a composition for cosmetic use.
• said methods aim at obtaining a remedy for each detected SNP by recommending lists of active ingredients, which are already known for decades, in the treatment of aesthetic defects, without any evaluation of possible synergistic effects of said genetic variants.
• the object of the present invention is to provide a method for evaluating the health status of an individual's tissues, in particular of the cutaneous tissue.
• Another object is to obtain useful information for the treatment of an individual's skin through targeted genetic testing.
• An additional object is to obtain a method for preparing a custom cosmetic treatment according to an individual's skin health status.
• Another object is a method for evaluating genetic variants on responses to certain active ingredients or substances.
• this object is achieved by a method as described in claim 1.
• the DNA (deoxyribonucleic acid) is a long chain polymer that contains the genetic material; most living organisms have their own DNA.
• the DNA consists of four units that are repeated within the polymer, the so- called nucleotides, whose order determines a particular signal.
• the nucleotides in the DNA are: Guanine (G), Cytosine (C), Adenine (A) and Thymine (T).
• G Guanine
• C Cytosine
• A Adenine
• T Thymine
• Gene refers to a DNA segment that contains protein-encoding sequences, wherein the segment may include exons, introns, promoters or other non-transcribed regions.
• alleles are defined as the two or more alternative forms of the same gene which are located in the same position on each homologous chromosome (genetic locus). The alleles control the same character but can lead to quantitatively or qualitatively different products.
• haplotype single or simple
• haplotype defines the combination of allelic variants along a chromosome or a chromosomic segment containing loci in linkage disequilibrium, i.e., closely associated with each other, and which are usually inherited together.
• a genetic marker is a DNA portion with a known location on a chromosome and that can be used to identify individuals or species.
• the "genetic predisposition” is the susceptibility of a subject to a particular condition or pathology. Detecting a genetic predisposition can mean detecting a susceptibility or a pathology. In addition, by detecting a predisposition, it is possible to have predictive indications about a possible development of an interesting pathology or medical condition.
• a "polymorphism” is a variation of nucleotides within DNA that causes a change in the amino acid sequence of the protein.
• SNP single nucleotide polymorphism
• the present invention discloses a method for skin analysis to identify the skin health status. This method provides for the identification of genetic variants that may affect the skin health status and lead to blemishes and dysfunctions. The method uses individual human genetic information to identify the skin condition and to administer the best cosmetic product.
• the invention provides for the analysis of the possible relationship between the presence of nucleotides in sites that give rise to polymorphisms on genes associated with skin maintenance and alterations.
• the complex aetiology associated with skin imperfections is influenced by both genetic and environmental factors unique to each situation.
• these imperfections are caused by innumerable environmental, physiological and behavioural dynamics, such as the natural aging process, diet, sex, smoking, physical activity, allergens, UV exposure, sleep, hormones, the use of alcohol and tobacco.
• the method object of the present invention provides the evaluation of the most active or inactive metabolic pathways in an individual that regulate the skin maintenance.
• Said method firstly involves the analysis of said metabolic pathways through the biological material isolated from the individual.
• Said biological sample can be obtained by bioptic or surgical removal of the tissue, said tissue can be not-fixed, frozen, fixed in formalin and/or incorporated in paraformaldehyde; it may be saliva, tears, skin scrapes or other body fluids.
• the method therefore aims to obtain a custom genetic profile of each individual's skin.
• Said genetic profile can be obtained by the following process:
• DNA genomic sample for example from a skin, saliva or other tissue sample
• the analysis of said genes has allowed to specifically evaluate four groups of genes and divide them according to the process to which they are linked.
• the extracellular matrix is crucial for the consistency and elasticity of the skin and the wrinkle formation depends on it.
• the oxygen radical species (henceforth ROS) are chemically reactive molecules that make numerous chemical compounds unstable.
• the main ROS targets are DNA, proteins and membrane phospholipids.
• the ROS in the skin cause damage to the production of collagen and elastin, the main components of the extracellular matrix that functions to support and nourish the skin. This ROS action is one of the main causes of skin aging.
• a contrast action against ROS is carried out by glutathione, an antioxidant molecule.
• glutathione an antioxidant molecule.
• glutathione an antioxidant molecule.
• cysteine whose bioavailable form is N-acetylcysteine (NAC).
• the NAC is commonly used as mucolytic by oral or inhalation route, but other applications have also been described, such as intra-dermal administration thereof in combination with a solution of essential and nonessential amino acids (commonly used for parenteral nutrition).
• intra-dermal administration have been studied on cultured fibroblasts, obtaining a complete picture of the gene response of the major extracellular matrix components to that biochemical stimulus.
• the selected genes are:
• HAS 1 (Locus: 19ql3.41; MEVI (Mendelian Inherited in Man) 601463): hyaluronic acid synthetase.
• the HAS 1 up regulation leads to a higher cellular production of hyaluronic acid, causing a moisturizing, invigorating and volumetric restoration of the dermis.
• HYAL1 (Locus: 3p21.31; MIM 607071): hyaluronidase 1.
• the HYAL1 up regulation leads to an increase of hyaluronic acid catabolism, allowing a replacement of the extracellular matrix.
• ELANE (Locus: 19pl3.3; MIM 130130) elastase.
• the ELANE up regulation leads to an increase in elastin catabolism, allowing a turnover of the extracellular matrix.
• MMP2 (Locus: 16ql2.2; MIM120360) type A gelatinase.
• the MMP2 up regulation leads to an increase in the non-fibrillar collagen IV catabolism present in the basal membrane, allowing a replacement of the dermal composition.
• MMP3 (Locus: l lq22.2; MIM 185250) stromelysin.
• the MMP3 up regulation leads to an increase in the catabolism of extracellular matrix components such as proteoglycans, fibronectin, laminin and type IV collagen, allowing a replacement of the dermal composition.
• MMP13 (Locus: l lq22.2; MIM 600108) type III collagenase.
• the MMP13 up regulation leads to collagen I, II and III increased catabolism, allowing a replacement of the dermal composition.
• Photo-aging i.e., the UV rays mediated skin aging
• the photo-aged skin is characterized by a decrease in thickness and elasticity, dryness, alteration of the epidermal barrier and hyper- pigmentation.
• Many of the UV damages are mediated by ROS, that make many chemical compounds unstable and alter the connective tissue.
• the ROS action can be counteracted by antioxidant compounds.
• a group of genes involved in the maintenance of the connective tissue has been evaluated, particularly those genes that adjust the turnover of the major components of said connective tissue, such as collagen.
• AX is a carotenoid present mainly in algae and crustaceans (such as salmon, lobster, shrimp, crab, etc.) and has a well-known antioxidant, antiinflammatory and immunomodulatory activity.
• the AX main mode of action is to prevent and block the action of ROS by inhibiting the UV induced oxidative damage in cells, such as the peroxidation of lipids constituting the cell membrane.
• AX is poorly water-soluble, therefore liposomal formulations of AX (AX-lipo) have been prepared that allow the transcutaneous administration thereof.
• hydrolysed collagen responsible for the extracellular matrix synthesis and used with benefit to slow down skin aging, mainly caused by photo-aging.
• - COL1A1 (Locus: 17q21.33; MIM 120150): type 1 -alpha 1 collagen. Essential component of the extracellular skin matrix. The administration of AX-IdroCo induces the transcription of this gene by increasing the collagen production.
• fibrillin Essential component of the extracellular skin matrix.
• the AX-IdroCo administration induces the transcription of this gene by increasing the fibrillin production.
• the AX-IdroCo administration induces the transcription of this gene by increasing its production and consequently the amount of the produced hyaluronic acid.
• the melanogenesis is the biochemical process, carried out by melanocytes, leading to the formation of melanin.
• the melanogenesis is induced by UV rays and is a physiological process that protects epidermal cells from the attack of free radicals that cause DNA damage. However, this process accelerates skin aging and can give rise to unsightly, dark spots.
• the UVs indirectly influence the melanogenesis of melanocytes by a regulatory paracrine process involving keratinocytes.
• PEG2 and PGF2A are the major prostaglandins that constitute the mediators produced by keratinocytes in response to UVs.
• PEG2 and PGF2A are the major prostaglandins that constitute the mediators produced by keratinocytes in response to UVs.
• prostaglandins mediate post-inflammatory pigmentation changes by modulation of melanin and melanocytic dendrites synthesis.
• the receptor activated by type 2 protease is expressed in keratinocytes but not in melanocytes, and plays a key role in the regulation of the cyclooxygenase 2 enzyme (COX-2), which together with the PEG2 enzyme (prostaglandin E2 synthase), produces the prostaglandins, the inflammation mediators.
• PAR2 increases the transcription of COX-2 and the release of arachidonic acid, a precursor of prostaglandins, causing increased secretion of PGE2 and PGF2.
• PAR2 regulates the uptake of melanosomes in keratinocytes.
• the madecassoside (henceforth MA) is one of the major triterpene glycosides isolated from Centella Asiatica and has various skin effects, including an anti-inflammatory, anti-aging and protective effect against oxidative stress and UVB rays.
• the anti-inflammatory activity is due to the inhibition of COX-2 and PAR2 following exposure to UVB, thus reducing the production of prostaglandins.
• MA inhibits the phagocytosis of melanosomes, induces melanin synthesis, melanosome increase and melanocytic dendritogenesis.
• MA has been shown to be effective, in vitro, in increasing the production of type 1 and 3 collagens in fibroblasts.
• MA is poorly water-soluble, therefore MA liposomal formulations
• the MA effects have been studied in vitro obtaining a picture of the gene response of the main target genes of this compound.
• - PAR2 (o F2RL1) (Locus 5Q13.3; MIM 600933): receptor activated by type 2 proteases. It regulates the COX-2 enzyme.
• the MA administration in the presence of UVBs, inhibits the transcription of this gene, by reducing the production of PEG2 and
• - COX-2 (or PTGS2) (Locus lq31.1; MIM 600262): type 2 cyclooxygenase or prostaglandin synthase 2. It catalyses the first step of conversion of arachidonic acid into prostaglandins.
• the MA administration in the presence of UVBs, inhibits the transcription of this gene, by inhibition of PAR2.
• - COL1A1 (Locus 17q21.33; MIM 120150): 1-alpha type 1 collagen. Essential component of the extracellular skin cell matrix. The MA administration induces the transcription of this gene by increasing the collagen production.
• Fibrillar essential component of the extracellular matrix of the skin The MA administration induces the transcription of this gene by increasing the collagen production.
• Retinoids are natural compounds that include vitamin A (retinol) and derivatives thereof, such as retinal and retinoic acid.
• Retinoic acid is considered the active form of vitamin A and is involved in different gene regulation pathways with effects on both proliferation and cell differentiation.
• the retinol is therefore a fundamental substance for skin growth and differentiation, and is metabolised in retinoic acid in skin fibroblasts (wrinkles, skin hyperpigmentation, acne, psoriasis) and improves the appearance of the skin (increased consistency and skin tone, increased elasticity).
• retinols have several side effects, including skin irritation, dryness, burning sensation, which limit the use thereof, for this reason retinol-like substances have been identified that, while retaining the specific effect of retinol, do not possess the retinol side effects.
• Bakuchiol is a meroterpene phenol present in the Psoralea Corylifolio plant, and it is one of those retinol-like compounds that has shown retinol-like effects and is used as anti-oxidant, anti-wrinkle and anti-acne.
• N6AMT1 (Locus 21q21.3; MIM 614553): N6 DNA adenine- specific methyltransferase 1. Bak down-regulates the expression of N6AMT1, reducing the retinol-like toxicity by decreasing the epigenetic modifications to DNA mediated by this enzyme.
• This enzyme is involved in the conversion of retinol to retinal and then into retinoic acid. Bak induces this enzyme by increasing the conversion of retinols.
• LRAT Lecithin-retinol acetyltransferase. This enzyme mediates the retinol esterification reaction with long chain fatty acids, key step to retinol uptake and storage.
• CRBPs are proteins involved in cellular internalization and retinol cellular transfer, retinol esterification, retinol esters hydrolysis, and oxidation from retinol to retinaldehyde (key passage in retinoic acid biosynthesis).
• the expression of these three CRBPs is induced by Bak, which thus increases the bioavailability of retinol at cellular level.
• the genes are analyzed by whole gene sequencing.
• composition for cosmetic use may be a cream, an ointment, a water in oil emulsion, an oil in water emulsion or any other type of emulsion, gel, paste, cataplasm, medicated poultice, medicated foam or medicated plaster.
• Said cosmetic composition may contain in addition to the active ingredients at least one excipient.
• Said at least one excipient may be a lipophilic excipient, such as an oleaginous base (petralatum, fats, silicones, isopropyl myristate, etc.), an absorbent base (lanolin, lanolin alcohols, lano-vaseline, etc.) or hydrophilic excipient such as for example ethylene oxide derivatives, polyethylene glycols, water, hydrocolloids such as starch, methylcellulose, carboxymethylcellulose, gelatin, carbopol, or any other excipient for cosmetic use.
• an oleaginous base petralatum, fats, silicones, isopropyl myristate, etc.
• an absorbent base lanolin, lanolin alcohols, lano-vaseline, etc.
• hydrophilic excipient such as for example ethylene oxide derivatives, polyethylene glycols, water, hydrocolloids such as starch, methylcellulose, carboxymethylcellulose, gelatin, carbopol, or any other excipient for
• composition for cosmetic use may also contain surfactants, preservatives, antioxidants, dyestuffs or fragrances, which may be selected according to the national regulations of the countries in which it will be marketed.
• said method for obtaining a custom composition for cosmetic use provides for the analysis of the four panels of genetic variants that will be analyzed together. At the end of the analysis, substances for cosmetic use will be administered which can also be prepared in the form of preparation for cosmetic use. The metabolic status of the pathways involved in the four panels chosen for the study will be evaluated.
• SNP rs61736495 of HAS 1 gene for the loss of skin elasticity
• SNP rs 1799750 on the MMP1 gene to evaluate the photo- aging
• SNPs rs689466 and rs20417 on COX2 gene to evaluate the presence of skin spots
• SNP rs 1059261 on DHRS9 gene to evaluate the loss of skin tone and the wrinkle formation.
• SNPs SNPs are closely related to the metabolic status of the pathway of interest and may affect its proper activation, therefore all the genes involved in the specific metabolic pathway will also be studied.
• the cosmetic composition will be prepared according to the indications detected from the analysis of the at least one SNP.
• the composition for cosmetic use comprises at least one of the following active ingredients:
• N-acetylcysteine to a final concentration between 5 and 50 mg/ml, preferably between 10 and 35 mg/ml, still more preferably between 15 and 25 mg/ml.
• Astaxanthine (AX) at a concentration between 0.5% and 2.5% by weight at 8 or 16 micronM in combination with Hydrolyzed Collagen.
• the AX will be contained in a liposomal preparation.
• the MA will be contained in a liposomal preparation.
• a sunscreen selected from a group comprising: ⁇ , ⁇ , ⁇ -Trimethyl- 4-(2-oxoborn-3-ylidenemethyl) anilinium methyl sulphate, Benzoic acid, 2-hydroxy,3,3,5-trimethylcyclohexyl ester/Homosalate, 2-Hydroxy-4-methoxybenzophenone, 2- Phenylbenzimidazole-5-sulphonic acid and its potassium, sodium and triethanolamine salts, 3,3'-(l,4-Phenylenedimethylene) bis (7,7-dimethyl-2-oxobicyclo-[2.2.1] hept- 1-ylmethanesulfonic acid) and its salts, l-(4-tert-Butylphenyl)-3-(4-methoxyphenyl)
• Bakuchiol at a concentration by weight between 2% and 15%, preferably between 4% and 12% by weight.
• the genetic panel relating to the loss of skin elasticity will be evaluated and in particular the HAS 1 gene will be analyzed to investigate the presence of SNP rs61736495. Also, the genes HYALl, ELANE, MMP2, MMP3 and MMP13 will be studied.
• a cosmetic composition comprising a solution of essential and non-essential amino acids (L- isoleucine at a concentration by weight between 0.4% and 0.65%, L-leucine at a concentration by weight between 0.65% and 0.85 %, L-lysine monochlorohydrate at a concentration by weight between 0.65% and 0.85%, L-methionine at a concentration by weight between 0.3% and 0.5%, L- phenylalanine at a concentration by weight between 0.3% and 0.5%, L- threonine at a concentration by weight between 0.25% and 0.40%, L- tryptophan at a concentration by weight between 0.05 % and 0.2%, L-valine at a concentration by weight between 0.4% and 0.65%, L-alanine at a concentration by weight between 0.4% and 0.65%, L-arginine at a concentration by weight between 0.7% and 0.9%, L-histidine hydrochloride at a concentration by weight
• the amino acids are dissolved in the physiological solution at a concentration between 3 and 12% by weight, preferably between 5 and 10%, still more preferably between 7 and 9%.
• NAC will have a final concentration between 5 and 50 mg/ml, preferably between 10 and 35 mg/ml, still more preferably between 15 and 25 mg/ml.
• the genetic panel regarding the loss of skin elasticity will be evaluated and in particular the HAS 1 gene will be analyzed to investigate the presence of SNP rs61736495. Also, the genes HYAL1, ELANE, MMP2, MMP3 and MMP13 will be studied.
• a cosmetic composition comprising a solution of essential and non-essential amino acids (L- isoleucine at a concentration by weight between 0.4% and 0.65%, L-leucine at a concentration by weight between 0.65% and 0.85%, L-lysine monochlorohydrate at a concentration by weight between 0.65% and 0.85%, L-methionine at a concentration by weight between 0.3% and 0.5%, L- phenylalanine at a concentration by weight between 0.3% and 0.5%, L- threonine at a concentration by weight between 0.25% and 0.40%, L- tryptophan at a concentration by weight between 0.05% and 0.2%, L-valine at a concentration by weight between 0.4% and 0.65%, L-alanine at a concentration by weight between 0.4% and 0.65%, L-arginine at a concentration by weight between 0.7% and 0.9%, L-histidine hydrochloride at a concentration by weight between 0.1
• the amino acids are dissolved in the physiological solution at a concentration between 3 and 12% by weight, preferably between 5 and 10%, still more preferably between 7 and 9%.
• the genetic panel relating to the photo-aging will be evaluated and in particular the MMP1 gene will be examined to investigate the presence of SNP rsl799750.
• COL1A1, FBN1, HAS2, MMP1 and MMP12 genes will also be studied.
• a cosmetic composition will be prepared comprising 8 microM liposomal AX at a concentration between 0.5 and 1.2% by weight.
• said AX is associated with hydrolysed collagen (IdroCo).
• the genetic panel relating to the photo-aging will be evaluated and in particular the MMP1 gene will be examined to investigate the presence of SNP rsl799750.
• COL1A1, FBN1, HAS2, MMP1 and MMP12 genes will also be studied.
• a cosmetic composition will be prepared comprising a 16 microM liposomal AX at a concentration between 1.4% and 2.5% by weight, preferably between 0.1 and 0.25% by weight.
• said AX is associated with hydrolysed collagen (IdroCo).
• the genetic panel relating to the presence of skin spots will be evaluated and in particular the COX2 gene will be examined to investigate the presence of SNPs rs689466 and rs20417.
• the PAR2, COX-2, COL1A1 and COL3A1 genes will also be studied.
• a cosmetic composition comprising liposomal MA will be prepared at a concentration between 0.5 and 1.5% by weight, preferably between 0.8 and 1.25% by weight.
• said MA is associated with a sunscreen with Solar Protection Factor (SPF) between 30 and 50.
• SPF Solar Protection Factor
• a cosmetic composition comprising liposomal MA will be prepared at a concentration between 0.5 and 1.5% by weight, preferably between 0.8 and 1.25% by weight.
• said MA is associated with a sunscreen with SPF between 6 and 25.
• the genetic panel relating to the loss of skin tone and wrinkle formation will be evaluated and in particular the DHRS9 gene will be analyzed to investigate the presence of SNP rs 1059261.
• the genes N6AMT1, DHRS9, LRAT, CRBPl, CRBP2 and CRBP4 will also be studied.
• a cosmetic composition comprising Bak at a concentration between 2% and 10% by weight, preferably between 4% and 8% by weight, will be prepared.
• the genetic panel relating to the loss of the skin tone and wrinkle formation will be evaluated and in particular the DHRS9 gene will be analyzed to investigate the presence of SNP rs 1059261.
• the genes N6AMT1, DHRS9, LRAT, CRBPl, CRBP2 and CRBP4 will also be studied.
• a cosmetic composition comprising Bak at a concentration from 4 to 13% by weight, preferably from 6 to 12% by weight, will be prepared.
• said method allows a custom preparation of the cosmetic composition, dosing in a specific manner the amounts of active ingredients to be added to each different type of cosmetic composition.
• Another advantage is that this method allows to analyze several aspects of a tissue and to evaluate the overall health status.
• Another advantage is that this method provides for the analysis of selected ad hoc SNPs allowing a targeted tissue health analysis avoiding time and money waste.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Dermatology (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57750384

Family Applications (1)

Country Status (3)

Family Cites Families (4)

• 2016
  • 2016-06-23 IT ITUA2016A004627A patent/ITUA20164627A1/it unknown
• 2017
  • 2017-06-21 EP EP17751124.3A patent/EP3474813A1/de not_active Withdrawn
  • 2017-06-21 WO PCT/IB2017/053682 patent/WO2017221161A1/en unknown

Also Published As

Similar Documents

Legal Events